Fucose sugar may help prevent liver cancer from spreading

8733b6be-35c4-4eae-820f-af5db470ea4farticleimage.jpg

13 Oct 2017 --- Researchers at the RIKEN Global Research Cluster in Japan have discovered a way in which fucose sugar can prevent the spread of cancer in the liver. Published in the journal Cell Chemical Biology, the study details how treatment with a modified fucose sugar can disrupt a biological pathway, which in turn blocks hepatoma – cancer cells in the liver – from invading healthy liver cells.

Many important biological functions depend on a process called glycosylation, which is the attachment of sugars to other molecules such as proteins, lipids, or other sugars. When the sugar fucose (Fuc) is attached to a chain of sugars called glycans, they are said to be fucosylated.

“Fucosylated glycans are critical in several cellular processes that affect development and immunity,” says first author Yasuhiko Kizuka. “At the same time, defective fucosylation can lead to life-threatening diseases.”

One such disease is liver cancer, in which hepatoma are known to have excessive levels of fucosylated glycans. The RIKEN team reasoned that treatment targeting fucosylation in these cells might be effective in treating cancer.

Strategy for fucosylation
Biological pathways are chains of events in which a series of molecules interact with each other step by step, usually with the help of enzymes. In this case, several events transform glucose into a compound called GDP-fucose. An enzyme then detaches fucose from GDP and joins it to a glycan.

One way to inhibit this type of biological signaling process is to introduce molecular analogs – molecules that are similar to those needed in the chain of interactions.

The team at RIKEN used this strategy and compared the effects of two fucose analogs on fucosylation. Using several different types of cells, they found that one of them, 6-Alk-Fuc, virtually abolished all cellular fucosylation.

The next step was to determine how fucosylation was blocked. Experiments showed that the analog did not prevent the transfer of fucose from GDP-fucose to glycans, indicating that fucosylation itself was not affected.

The team reasoned that the effect must occur earlier in the chain of events. Additional experiments showed that 6-Alk-Fuc blocked GDP-mannose from becoming GDP-fucose.

As Kizuka explains: “The analog competed with GDP-mannose for attention from the enzyme FX, which prevented fucose from being made from GDP-fucose, making it impossible for downstream fucosylation to occur.”

With this knowledge in hand, the team was able to test whether the 6-Alk-Fuc has the potential to treat liver cancer. Using several cell lines of a hematoma that had excessive levels of fucosylated glycans, the team found that the analog was able to prevent healthy extracellular matrix from being invaded by the hepatoma, and was able to suppress migration of some hepatoma cell lines.

However, while it suppressed invasion, the treatment did not suppress hepatoma proliferation, meaning that the number of cancer cells continued to increase, even though they could not harm the healthy cells.

Kizuka says that the invasion-suppressive properties of this fucose analog make it a potentially promising treatment for suppressing cancer metastasis in Fuc-high cancers such as those found in the liver.

Related Articles

Nutrition & Health News

Chronic heavy drinking major risk factor for dementia: The Lancet

21 Feb 2018 --- Excessive alcohol use is a major risk factor for onset of all types of dementia, especially early-onset dementia, according to a French nationwide observational study, published in The Lancet Public Health journal. Previous research has shown mixed results regarding the effect of alcohol on cognitive health, with some studies showing a possible benefit of light to moderate drinking, while others have found detrimental effects of heavy drinking on dementia risk.

Nutrition & Health News

Low-fat and low-carb diets equally effective, Stanford study finds

21 Feb 2018 --- After years of debate, a new study at the Stanford University School of Medicine has found that neither a low-fat nor a low-carb diet is superior: Cutting either carbs or fats leads to a reduction of excess weight in about the same proportion, according to the study. The study also looked into whether insulin levels or a specific genotype pattern could predict an individual's success on either diet. The answer, in both cases, was no.

Business News

Lonza to expand Florida encapsulation capabilities amid product development acceleration

21 Feb 2018 --- Swiss multinational, chemicals and biotechnology company, the Lonza Group is planning to expand its late-stage clinical and commercial encapsulation capabilities for solid oral and inhaled dosage forms in North America. The company will install a new Harro Hӧfliger Modu-C MS encapsulation unit (Harro unit) at its integrated product development and manufacturing facility in Tampa, Florida, to strengthen production and bring its products to market faster. 

Nutrition & Health News

Gluten-free bakery: Growing demand for products with extra nutritional benefits, DuPont survey reveals

20 Feb 2018 --- European consumers are looking for gluten-free bakery products that match regular products in terms of taste and texture, but also offer additional health benefits such as high fiber, a DuPont Nutrition & Health consumer survey has revealed. The survey results show untapped potential for bakers to develop more and better-quality products with extra nutritional benefits, and the company notes that customized ingredient solutions are the way to tapping into this potential.

Nutrition & Health News

ExcelVite palm tocotrienol complex eases severe pain, diabetic patient study reveals

20 Feb 2018 --- Researchers at the University Science of Malaysia have found that daily doses of EVNol SupraBio – a bio-enhanced full spectrum palm tocotrienol complex – can help to relieve severe pain (lancinating pain) in diabetic neuropathy patients. Focusing on diabetic neuropathy patients (DPN), this Vitamin E Neuroprotection Study (VENUS) was a randomized, double-blind clinical trial carried out to discover how to better manage the challenging issue of painful neuropathy. It is the largest tocotrienol human clinical study of its kind. 

More Articles
URL : http://www.nutritioninsight.com:80/news/fucose-sugar-may-help-prevent-liver-cancer-from-spreading.html